Clinical Trial Detail

NCT ID NCT02094573
Title A Phase 2, Multicenter, Randomized Study of AP26113
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Ariad Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Brigatinib

Age Groups: adult

Additional content available in CKB BOOST